MAPPING ACROQOL SCORES TO EQ-5D TO OBTAIN UTILITY VALUES FOR PATIENTS WITH ACROMEGALY
Author(s)
Badia X1, Biermasz N2, Tiemensma J3, Carreno A4, Roset M4, Forsythe A5
1Omakase Consulting, Barcelona, Spain, 2Center of Endocrine Tumors Leiden. University Medical Center, Leiden, The Netherlands, 3University of California Merced, Merced, CA, USA, 4QuintilesIMS, Barcelona, Spain, 5Purple Squirrel Economics, New York, NY, USA
OBJECTIVES: Estimate a preference-based single index for disease specific instrument (AcroQOL) by mapping it onto the EQ-5D for future economic evaluations METHODS: RESULTS: Mean(SD) scores for AcroQoL Global Score and EQ-5D utility were 62.3(18.5) and 0.71(0.28), respectively. The best model for predicting EQ-5D was a generalized regression model that included the Physical Dimension summary score and categories from questions 9 and 14 as independent variables (Adj. R2=0.56, with mean absolute error of 0.0128 in confirmatory sample): Utility=0.30778+0.00734xPhysical score-0.23227xAcroqol item 9-0.07128*Acroqol item 14 (categories 1 or 2). Observed and predicted utilities were strongly correlated (Spearman r=0.73, p<0.001) and paired t-tests revealed non-significant differences between means (p>0.05). Estimated utility scores showed minimum error of ≤10% in 45% of patients; however, error increased in patients with observed utility score under 0.2. The model’s predictive ability was confirmed in the second sub-sample. CONCLUSIONS: A mapping algorithm was developed for mapping of AcroQoL to EQ-5D, using patient level data from 3 previously published studies, and including validation in confirmatory sub-sample. Mean(SD) utilities index in this study population was estimated as 0.71(0.28). Additional research may be needed to test this mapping algorithm in other acromegaly populations.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PDB57
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders